Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03564821
Title IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Ivosidenib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST